| Date | Title | | | | 05/08/13 | Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results| ALISO VIEJO, Calif., May 8, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2013.
(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)
Quarterly Financial Highlights
Total company net revenues of $17.4 million
Gross and net NUEDEXTA® sales increased to $20.8 million and $16.5 million, respectively, representing growth of 14% and 11% versus the previous quarter
Cash, cash equi... |
| |  | | 05/01/13 | Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call| ALISO VIEJO, Calif., May 1, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will report financial results for the quarter ended March 31, 2013 after market close on Wednesday May 8, 2013. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Conference Call Information:
Domestic callers: 1 (877) 703 6106
International callers: +1 (857) 244-7305
Passcode: 62763985
Webcast information: Visit http:/... |
| | | | 04/26/13 | Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe| NUEDEXTA recommended for the treatment of PBA, irrespective of neurologic cause
ALISO VIEJO, Calif., April 26, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect (PBA), irrespective of neu... |
| | | | 03/11/13 | Avanir Pharmaceuticals Announces Appointment of Corinne Nevinny to Board of Directors|
ALISO VIEJO, Calif., March 11, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the appointment of Ms. Corinne Nevinny to the company's board of directors. Ms. Nevinny, a seasoned life sciences executive joins Avanir's board with broad healthcare industry experience across multiple disciplines.
(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)
Ms. Nevinny is General Partner of LMNVC LLC, a privately held early stage venture firm, which she... |
| | | | 03/06/13 | AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY| Veterans with TBI at Risk for Debilitating Condition, Pseudobulbar Affect, Causing Uncontrollable Crying and/or Laughing Outbursts
ALISO VIEJO, Calif., March 6, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) in collaboration with the Department of Veterans Affairs (VA) and United BioSource Corporation (UBC) today announced a pilot study to screen for pseudobulbar affect (PBA) symptoms in approximately 1,000 veterans with traumatic brain injury (TBI) . Accordi... |
| | | | 03/01/13 | Avanir Pharmaceuticals To Participate in Two Conferences in March|
ALISO VIEJO, Calif., March 1, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in March.
(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)
Cowen & Company 33rd Annual Healthcare Conference
Location: Boston Marriott Copley Place, Boston, MA
Presentation date: Tuesday March 5, 2013
Presentation time: 9:20 a.m. E.T.
... |
| | | | 02/14/13 | Avanir Pharmaceuticals To Present At RBC Capital Markets' 2013 Global Healthcare Conference|
ALISO VIEJO, Calif., Feb. 14, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the RBC Capital Markets' 2013 Global Healthcare Conference.
Location: Palace Hotel, New York, NY
Presentation date: Tuesday February 26, 2013
Presentation time: 4:35 p.m. ET
A live webcast and 30-day archive of this presentation will be available at http://ir.avanir.com.
About Avanir Pharmaceutical... |
| | | | 02/07/13 | Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786|
ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that it has successfully completed the first of a two-stage pharmacokinetic study with AVP-786, a drug product containing a deuterium modified form of dextromethorphan. Based on interim data, Avanir believes that it has identified a formulation of AVP-786 with a comparable pharmacokinetic, safety and tolerability profile to AVP-923 (dextromethorphan hydrobromide and quinidine sulfate... |
| | | | 02/07/13 | Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results|
ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2012.
(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)
Quarterly Financial Highlights
Total company net revenues increased to $16.5 million, representing growth of 22% versus the previous quarter
Gross and net NUEDEXTA® sales increased to $18.4 million and $14.9 million, respectively, representing g... |
| | | | 01/30/13 | Avanir Pharmaceuticals Announces Date Of Fiscal 2013 First Quarter Financial Results And Conference Call|
ALISO VIEJO, Calif., Jan. 30, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) will report financial results for the quarter ended December 31, 2012 after market close on Thursday February 7, 2013. The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Conference Call Information:
Domestic callers: 1 (866) 783-2141
International callers: +1 (857) 350-1600
Passcode: 51423033
Webcas... |
| | |
|
